Leila Pirhaji
| Leila Pirhaji | |
|---|---|
| Born | Iran |
| 🎓 Alma mater | University of Tehran Massachusetts Institute of Technology (PhD) |
| 💼 Occupation | |
| 🌐 Website | revive-med |
Leila Pirhaji is an Iranian scientist and entrepreneur. She is the founder and CEO of the biotech start-up ReviveMed, which raised $1.5 million in 2018.[3] ReviveMed analyses metabolomic data using artificial intelligence, which allows them to design new medical therapeutics.
Early life and education[edit]
Pirhaji earned a Bachelor's degree in Biotechnology from the University of Tehran in 2008 and a Master's degree in 2010.[4] She began working on metabolomics during her doctoral studies at the Massachusetts Institute of Technology (MIT).[3] She studied the interactions between proteins and metabolites.[3] During her PhD, she worked as an intern at Merck & Co.[4] She recognised that machine learning could be useful to analyse these interactions. Together with her advisor Ernest Fraenkel, Pirhaji founded ReviveMed.[3] She completed her PhD at MIT in 2016,[2][1]
Career and research[edit]
Following her PhD, she received funding from StartMIT, StartIAP, MIT100K and the Sandbox Innovation Fund Program.[5][6] In 2016, ReviveMed was selected as a winner of the MassChallenge, Boston.[7]
ReviveMed[edit]
ReviveMed can distinguish similar mass metabolites and correlate them to drugs, protein effects and the outcomes of disease.[3] The company translates data from metabolites into therapeutic solutions.[8] She is working on untreatable diseases which have shown a good chance of treatment.[3] Pirhaji is one of the first to use large-scale metabolomic data to treat these diseases.[6] She secured $1.5 million in a seed round in 2018 and $200,000 at a Google machine learning competition.[3] She became Chief Executive Officer in 2017.[9] Their technology was published in Nature Methods.[10] ReviveMed won the BioTech Award at the ExtremeTech Challenge 2018.[11]
Views[edit]
Pirhaji is concerned about Donald Trump's travel ban.[12]
References[edit]
- ↑ 1.0 1.1 Leila Pirhaji publications indexed by Google Scholar
- ↑ 2.0 2.1 Pirhaji, Leila (2016). Revealing disease-associated pathways and components by systematic integration of large-scale biological data. dspace.mit.edu (PhD thesis). MIT. hdl:1721.1/104227. OCLC 958142368.
- ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 Coldewey, Devin (2018-04-18). "ReviveMed turns drug discovery into a big data problem and raises $1.5M to solve it". TechCrunch.com. Retrieved 2018-07-30.
- ↑ 4.0 4.1 "Bloomberg Executive Profile". bloomberg.com. Bloomberg. Retrieved 2018-07-30.
- ↑ "ReviveMed team won $10K Booz Allen Hamilton analytics prize of MIT $100K competition, awarded to the most innovative analytic solution in businesses". revive-med.com. ReviveMed Technologies. 2016-05-12. Retrieved 2018-07-30.
- ↑ 6.0 6.1 Murphy, Meg (2016-06-02). "At MIT, a culture of innovation 'never gets old'". MIT News. Retrieved 2018-07-30.
- ↑ "ReviveMed was selected as a top 26 winners of MassChallenge Boston 2017. - ReviveMed Technologies". ReviveMed Technologies. 2017-10-05. Retrieved 2018-07-30.
- ↑ "Leila Pirhaji ReviveMed - PMWC Precision Medicine World Conference". PMWC Precision Medicine World Conference. Retrieved 2018-07-30.
- ↑ Khosravi, Bijan (2018-03-08). "How Persian Women Entrepreneurs Are Changing The Tech Industry". Forbes. Retrieved 2018-07-30.
- ↑ Pirhaji, Leila; Milani, Pamela; Leidl, Mathias; Curran, Timothy; Avila-Pacheco, Julian; Clish, Clary B; White, Forest M; Saghatelian, Alan; Fraenkel, Ernest (2016). "Revealing disease-associated pathways by network integration of untargeted metabolomics". Nature Methods. 13 (9): 770–776. doi:10.1038/nmeth.3940. ISSN 1548-7091. PMC 5209295. PMID 27479327.
- ↑ "ReviveMed is the BioTech Winner of Extreme Tech Challenge 2018. - ReviveMed Technologies". ReviveMed Technologies. 2018-01-12. Retrieved 2018-07-30.
- ↑ Stendahl, Max (2017-01-31). "Iranian MIT grad and biotech CEO fears for future after Trump ban". bizjournals.com. Retrieved 2018-07-30.
This article "Leila Pirhaji" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Leila Pirhaji. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
